Tatjana Radosavljevic, MD, PhD, is a Full Professor of Pathophysiology at the Institute of Pathophysiology “Ljubodrag Buba Mihailovic”, Faculty of Medicine University of Belgrade (MFUB). She obtained her Ph.D. from the Institute Pathophysiology of MFUB in 1999. She is Head of Laboratory of Experimental hepatology at MFUB. Also, she has extensive experience in research project teamwork and management. With extensive experience in biomedical research, she has developed broad expertise in pathophysiology, biochemistry, and pharmacology. She has successfully established and employed a wide range of experimental models for chronic liver diseases, including alcohol-related liver disease, MASLD, hepatic fibrosis, and both acute and chronic liver insufficiency. Her research also encompasses related conditions such as obesity, metabolic syndrome, and disorders involving the endocannabinoid system. Her research is centered on elucidating the molecular mechanisms underlying the pathophysiology of MASLD, with particular focus on mitochondrial dysfunction, endoplasmic reticulum stress, oxidative stress, inflammation, and fibrosis. She investigates key biomarkers, therapeutic targets, and potential pharmacological agents (betaine, alpinetin...) aimed at improving disease outcomes. Prof. Radosavljević has published a large number of bibliographic units, she was cited 1215 times (SCOPUS), with h index 19 (SCOPUS) (status as of June 5, 2025) (https://orcid.org/0000-0002-1701-3313)
Tatjana Radosavljevic, MD, PhD, is a Full Professor of Pathophysiology at the Institute of Pathophysiology “Ljubodrag Buba Mihailovic”, Faculty of Medicine University of Belgrade (MFUB). She obtained her Ph.D. from the Institute Pathophysiology of MFUB in 1999. She is Head of Laboratory of Experimental hepatology at MFUB. Also, she has extensive experience in research project teamwork and management. With extensive experience in biomedical research, she has developed broad expertise in pathophysiology, biochemistry, and pharmacology. She has successfully established and employed a wide range of experimental models for chronic liver diseases, including alcohol-related liver disease, MASLD, hepatic fibrosis, and both acute and chronic liver insufficiency. Her research also encompasses related conditions such as obesity, metabolic syndrome, and disorders involving the endocannabinoid system. Her research is centered on elucidating the molecular mechanisms underlying the pathophysiology of MASLD, with particular focus on mitochondrial dysfunction, endoplasmic reticulum stress, oxidative stress, inflammation, and fibrosis. She investigates key biomarkers, therapeutic targets, and potential pharmacological agents (betaine, alpinetin...) aimed at improving disease outcomes. Prof. Radosavljević has published a large number of bibliographic units, she was cited 1215 times (SCOPUS), with h index 19 (SCOPUS) (status as of June 5, 2025) (https://orcid.org/0000-0002-1701-3313)